Dapagliflozin Pretreatment Prevents Cardiac Electrophysiological Changes in a Diet and Streptozotocin Induction of Type 2 Diabetes in Rats: A Potential New First-Line?

Overview

Journal J Exp Pharmacol

Publisher Dove Medical Press

Date 2024 Mar 25

PMID 38525051

Authors

Prabhjot Kaur Juttla

Boniface Mwangi Chege

Peter Waweru Mwangi

Frederick Bukachi

Affiliations

Soon will be listed here.

Abstract

Purpose: Dapagliflozin exerts cardioprotective effects in Type 2 Diabetes Mellitus (T2DM). However, whether these effects prevent electrocardiographic changes associated with T2DM altogether remain unknown. Our aim was to investigate the prophylactic effect of dapagliflozin pretreatment on the rat ECG using a high-fat, high-fructose (HFHf) diet and a low dose streptozotocin (STZ) model of T2DM.

Methods: Twenty-five (25) rats were randomized into five (5) groups: normal control receiving a normal diet while the other groups received an 8-week HFHf and 40mg/kg STZ on day 42, and either: saline for the diabetic control (1 mg/kg/d), low dose (1.0 mg/kg/d) and high dose dapagliflozin (1.6 mg/kg/d), or metformin (250 mg/kg/d). Oral glucose tolerance (OGT), electrocardiograms (ECGs), paracardial adipose mass, and left ventricular fibrosis were determined. Data were analyzed using GraphPad version 9.0.0.121, with the level of significance at p < 0.05.

Results: Compared to the diabetic control group, a high dose of dapagliflozin preserved the OGT (p = 0.0001), QRS-duration (p = 0.0263), QT-interval (p = 0.0399), and QTc intervals (p = 0.0463). Furthermore, the high dose dapagliflozin group had the lowest paracardial adipose mass (p = 0.0104) and fibrotic area (p = 0.0001). In contrast, while metformin showed favorable effects on OGT (p = 0.0025), paracardial adiposity (p = 0.0153) and ventricular fibrosis (p = 0.0291), it did not demonstrate significant antiarrhythmic effects.

Conclusion: Pretreatment with higher doses of Dapagliflozin exhibits prophylactic cardioprotective characteristics against diabetic cardiomyopathy that include antifibrotic and antiarrhythmic qualities. This suggests that higher doses of dapagliflozin could be a more effective initial therapeutic option in T2DM.

References

Nantsupawat T, Wongcharoen W, Chattipakorn S, Chattipakorn N . Effects of metformin on atrial and ventricular arrhythmias: evidence from cell to patient. Cardiovasc Diabetol. 2020; 19(1):198. PMC: 7687769. DOI: 10.1186/s12933-020-01176-4. View

Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A . Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018; 380(4):347-357. DOI: 10.1056/NEJMoa1812389. View

Maejima Y . SGLT2 Inhibitors Play a Salutary Role in Heart Failure via Modulation of the Mitochondrial Function. Front Cardiovasc Med. 2020; 6:186. PMC: 6960132. DOI: 10.3389/fcvm.2019.00186. View

Kumar A . Effectively communicating the 5R's (replace, reduce, refine, reuse, and rehabilitate) of research ethics, biomedical waste, personalized medicines and the rest. J Nat Sci Biol Med. 2012; 3(1):1-2. PMC: 3361767. DOI: 10.4103/0976-9668.95932. View

Yagi S, Hirata Y, Ise T, Kusunose K, Yamada H, Fukuda D . Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2017; 9:78. PMC: 5628447. DOI: 10.1186/s13098-017-0275-4. View

Pabon M, Manocha K, Cheung J, Lo J . Linking Arrhythmias and Adipocytes: Insights, Mechanisms, and Future Directions. Front Physiol. 2018; 9:1752. PMC: 6290087. DOI: 10.3389/fphys.2018.01752. View

Mauricio D, Alonso N, Gratacos M . Chronic Diabetes Complications: The Need to Move beyond Classical Concepts. Trends Endocrinol Metab. 2020; 31(4):287-295. DOI: 10.1016/j.tem.2020.01.007. View

Oikonomou E, Antoniades C . The role of adipose tissue in cardiovascular health and disease. Nat Rev Cardiol. 2018; 16(2):83-99. DOI: 10.1038/s41569-018-0097-6. View

Filardi T, Ghinassi B, Di Baldassarre A, Tanzilli G, Morano S, Lenzi A . Cardiomyopathy Associated with Diabetes: The Central Role of the Cardiomyocyte. Int J Mol Sci. 2019; 20(13). PMC: 6651183. DOI: 10.3390/ijms20133299. View

10.

Testa R, Bonfigli A, Prattichizzo F, La Sala L, De Nigris V, Ceriello A . The "Metabolic Memory" Theory and the Early Treatment of Hyperglycemia in Prevention of Diabetic Complications. Nutrients. 2017; 9(5). PMC: 5452167. DOI: 10.3390/nu9050437. View

11.

Ye Y, Bajaj M, Yang H, Perez-Polo J, Birnbaum Y . SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. Cardiovasc Drugs Ther. 2017; 31(2):119-132. DOI: 10.1007/s10557-017-6725-2. View

12.

Dhingra R, Pencina M, Wang T, Nam B, Benjamin E, Levy D . Electrocardiographic QRS duration and the risk of congestive heart failure: the Framingham Heart Study. Hypertension. 2006; 47(5):861-7. DOI: 10.1161/01.HYP.0000217141.20163.23. View

13.

Daniele G, Xiong J, Solis-Herrera C, Merovci A, Eldor R, Tripathy D . Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes. Diabetes Care. 2016; 39(11):2036-2041. PMC: 5079607. DOI: 10.2337/dc15-2688. View

14.

Konopelski P, Ufnal M . Electrocardiography in rats: a comparison to human. Physiol Res. 2016; 65(5):717-725. DOI: 10.33549/physiolres.933270. View

15.

Solomon S, Zelenkofske S, McMurray J, Finn P, Velazquez E, Ertl G . Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005; 352(25):2581-8. DOI: 10.1056/NEJMoa043938. View

16.

Chege B, Waweru M, Frederick B, Nyaga N . The freeze-dried extracts of Rotheca myricoides (Hochst.) Steane & Mabb possess hypoglycemic, hypolipidemic and hypoinsulinemic on type 2 diabetes rat model. J Ethnopharmacol. 2019; 244:112077. DOI: 10.1016/j.jep.2019.112077. View

17.

Sato T, Aizawa Y, Yuasa S, Kishi S, Fuse K, Fujita S . The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol. 2018; 17(1):6. PMC: 5753537. DOI: 10.1186/s12933-017-0658-8. View

18.

Filippatos T, Liontos A, Papakitsou I, Elisaf M . SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses. Postgrad Med. 2019; 131(2):82-88. DOI: 10.1080/00325481.2019.1581971. View

19.

Ni L, Yuan C, Chen G, Zhang C, Wu X . SGLT2i: beyond the glucose-lowering effect. Cardiovasc Diabetol. 2020; 19(1):98. PMC: 7320582. DOI: 10.1186/s12933-020-01071-y. View

20.

Ritchie R, Abel E . Basic Mechanisms of Diabetic Heart Disease. Circ Res. 2020; 126(11):1501-1525. PMC: 7251974. DOI: 10.1161/CIRCRESAHA.120.315913. View